カルバペネムの世界市場

カルバペネムの世界市場は2030年までに47億米ドルに達する見込み

2024年に38億米ドルと推定されるカルバペネムの世界市場は、2024年から2030年にかけてCAGR 3.5%で成長し、2030年には47億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるメロペネム医薬品は、CAGR 4.2%を記録し、分析期間終了時には21億米ドルに達すると予測されます。イミペネム医薬品セグメントの成長率は、分析期間中CAGR 3.5%と推定されます。

米国市場は10億米ドルと推定、中国はCAGR 6.7%で成長予測

米国のカルバペネム市場は2024年に10億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.7%として、2030年までに9億4,540万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.7%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界のカルバペネム市場- 主要動向と促進要因のまとめ

なぜカルバペネム抗生物質の需要が増加しているのか？

カルバペネム系抗生物質は、特に多剤耐性（MDR）病原体による重篤な細菌感染症の治療に使用されるβ-ラクタム系抗生物質の重要なクラスです。抗菌薬耐性（AMR）が世界の脅威となるにつれ、カルバペネム系抗生物質は、院内感染、敗血症、肺炎、複雑性尿路感染症（cUTI）に対する最後の砦として、ますます頼りにされるようになってきています。カルバペネム耐性腸内細菌科細菌（CRE）、緑膿菌、Acinetobacter baumanniiを含む薬剤耐性菌の増加により、先進国および開発途上国の両方のヘルスケアシステムにおいて、これらの強力な抗生物質に対する需要が高まっています。

特に集中治療室（ICU）や免疫不全患者における院内感染の増加により、カルバペネムに基づく治療の必要性がさらに高まっています。ヘルスケアプロバイダーが生命を脅かす感染症に対するより効果的な解決策を模索する中、製薬会社はカルバペネム抗生物質のポートフォリオを拡大しており、単独療法として、あるいは耐性と闘うためにβ-ラクタマーゼ阻害剤と組み合わせて使用しています。AMRの継続的な増加や感染対策の強化が世界的に推進される中、カルバペネム抗生物質の需要は大きく伸びると予想されます。

技術の進歩は、カルバペネムの有効性と開発をどのように改善しているのか？

製薬研究と製剤における技術革新は、カルバペネム抗生物質の有効性、安定性、耐性との戦い能力を向上させています。最も注目すべき進歩の一つは、メロペネム・バボルバクタムやイミペネム・レバクタムのような新規のカルバペネム・ベタラクタマーゼ阻害剤（BLI）併用療法の開発であり、これらは耐性菌株を効果的に標的とします。これらの併用療法は、カルバペネム耐性腸内細菌科やその他の治療困難な病原体に対して優れた有効性を示し、病院環境において不可欠なものとなっています。

もうひとつの重要なブレークスルーは、カルバペネム製剤の薬物動態を改善するためのナノテクノロジーと標的ドラッグデリバリーシステムの利用です。リポソームカプセル化やその他の高度なデリバリーメカニズムが、毒性や副作用を抑えながら感染組織への薬剤浸透を高めるために研究されています。さらに、AIを活用した創薬プラットフォームにより、抗菌活性が改善され、耐性の可能性が低減された新規カルバペネムアナログの同定が加速しています。製剤と薬剤設計の継続的な進歩により、次世代のカルバペネム抗生物質は、増強された効力、広範なスペクトラム活性、耐性管理の改善を提供すると期待されています。

カルバペネム業界の成長を牽引する市場動向は？

抗菌薬耐性（AMR）の世界の負担の増加は、カルバペネム市場を形成する最も影響力のある動向の一つです。多剤耐性菌による感染症が増加し続ける中、病院やヘルスケアシステムは、抗菌薬管理プログラムにおいてカルバペネム系抗菌薬の使用を優先しています。FDA、EMA、WHOなどの政府および規制機関は、新規抗生物質療法の研究開発を積極的に推進しており、カルバペネムに基づく医薬品開発への投資の増加につながっています。

市場成長に影響を与えるもう一つの重要な動向は、特に新興市場におけるジェネリック医薬品の生産拡大です。ブランド抗生物質カルバペネムの特許が切れるにつれ、インド、中国、ブラジルなどの地域の製薬会社は手頃な価格のジェネリック製剤の生産を強化しており、中低所得国でも救命に役立つ抗生物質が入手しやすくなっています。さらに、院内感染（HAI）の増加や、複雑な医療処置を受ける免疫不全患者の増加が、世界中でカルバペネムの使用量を増加させています。AMR対策が重視されるようになり、カルバペネム系抗菌薬の世界の需要は、先発品、後発品ともに増加すると予想されます。

カルバペネム市場の将来を形作る主な成長促進要因は何か？

カルバペネム市場の成長は、薬剤耐性菌感染症の有病率の上昇、入院患者の増加、抗生物質併用療法の進歩など、いくつかの重要な要因によってもたらされます。主な成長要因の1つは、従来の抗生物質に対する耐性が増加しているグラム陰性菌に対する効果的な治療オプションの緊急ニーズです。ヘルスケアプロバイダーが重篤な感染症の管理に苦慮する中、カルバペネム系抗菌薬は抗菌薬療法に不可欠な要素であり続けています。

市場を形成するもう一つの重要な促進要因は、抗生物質の研究開発に対する政府および民間セクターの資金提供の拡大です。世界の医療機関や製薬企業は、AMRの危機に対処するため、革新的な製剤や耐性菌と闘う薬剤の組み合わせに投資しています。さらに、次世代のカルバペネムとBLIの組み合わせに対する規制当局の承認は、医療従事者により的を絞った効果的な治療の選択肢を提供し、市場の成長を加速させると予想されます。AMRとの戦いが続く中、カルバペネム市場は、技術革新、病院ベースの治療に対する需要の増加、最後の砦となる抗生物質の有効性を維持するための世界の取り組みによって、持続的な拡大が見込まれています。

セグメント

薬剤クラス別（メロペネム系薬剤、イミペネム系薬剤、エルタペネム系薬剤、その他薬剤クラス）、流通チャネル別（病院薬局流通チャネル、小売薬局流通チャネル、その他流通チャネル）、用途別（尿路感染症用途、血流感染症用途、腹腔内感染症用途、肺炎用途、その他用途）

調査対象企業の例

• ALPS Pharmaceutical Ind. Co., Ltd.
• AstraZeneca plc
• Asymchem Laboratories Inc.
• Aurobindo Pharma Ltd.
• Beijing Lunarsun Pharmaceutical Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Fresenius Kabi LLC
• GlaxoSmithKline plc
• High Science Co., Ltd.
• Jeil Pharmaceutical Co., Ltd.
• Meiji Holdings Co., Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Pharma Impex Laboratories Pvt. Ltd.
• Sandoz International GmbH
• Shionogi & Co., Ltd.
• Spero Therapeutics
• Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries Ltd.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Carbapenem Market to Reach US$4.7 Billion by 2030

The global market for Carbapenem estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Meropenem Drugs, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Imipenem Drugs segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Carbapenem market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$945.4 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Carbapenem Market - Key Trends & Drivers Summarized

Why Is the Demand for Carbapenem Antibiotics Increasing?

Carbapenems are a critical class of β-lactam antibiotics used to treat severe bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens. As antimicrobial resistance (AMR) becomes a growing global health threat, carbapenems are increasingly being relied upon as last-resort antibiotics for hospital-acquired infections, sepsis, pneumonia, and complicated urinary tract infections (cUTIs). The rising incidence of drug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii, has fueled the demand for these potent antibiotics in both developed and developing healthcare systems.

The increasing prevalence of nosocomial infections, particularly in intensive care units (ICUs) and immunocompromised patients, has further driven the need for carbapenem-based treatments. As healthcare providers seek more effective solutions for life-threatening infections, pharmaceutical companies are expanding their portfolios of carbapenem antibiotics, either as monotherapies or in combination with β-lactamase inhibitors to combat resistance. With the continued rise of AMR and the global push for stronger infection control measures, the demand for carbapenem antibiotics is expected to grow significantly.

How Are Technological Advancements Improving Carbapenem Efficacy and Development?

Innovations in pharmaceutical research and drug formulation are enhancing the efficacy, stability, and resistance-fighting capabilities of carbapenem antibiotics. One of the most notable advancements is the development of novel carbapenem-betalactamase inhibitor (BLI) combinations, such as meropenem-vaborbactam and imipenem-relebactam, which effectively target resistant bacterial strains. These combination therapies have demonstrated superior efficacy against carbapenem-resistant Enterobacteriaceae and other difficult-to-treat pathogens, making them essential in hospital settings.

Another key breakthrough is the use of nanotechnology and targeted drug delivery systems to improve the pharmacokinetics of carbapenem formulations. Liposomal encapsulation and other advanced delivery mechanisms are being explored to enhance drug penetration into infected tissues while reducing toxicity and side effects. Additionally, AI-driven drug discovery platforms are accelerating the identification of novel carbapenem analogs with improved antibacterial activity and reduced resistance potential. With continuous advancements in formulation and drug design, the next generation of carbapenem antibiotics is expected to offer enhanced potency, broader spectrum activity, and improved resistance management.

Which Market Trends Are Driving Growth in the Carbapenem Industry?

The increasing global burden of antimicrobial resistance (AMR) is one of the most influential trends shaping the carbapenem market. As infections caused by multidrug-resistant bacteria continue to rise, hospitals and healthcare systems are prioritizing the use of carbapenems in their antimicrobial stewardship programs. Governments and regulatory bodies, such as the FDA, EMA, and WHO, are actively promoting research and development in novel antibiotic therapies, leading to increased investments in carbapenem-based drug development.

Another key trend influencing market growth is the expansion of generic carbapenem production, particularly in emerging markets. As patents on branded carbapenem antibiotics expire, pharmaceutical companies in regions such as India, China, and Brazil are ramping up the production of affordable generic formulations, making these life-saving antibiotics more accessible in low- and middle-income countries. Additionally, the rise of hospital-acquired infections (HAIs) and the increasing number of immunocompromised patients undergoing complex medical procedures are driving higher carbapenem usage worldwide. With the growing emphasis on combating AMR, global demand for both branded and generic carbapenems is expected to rise.

What Are the Key Growth Drivers Shaping the Future of the Carbapenem Market?

The growth in the carbapenem market is driven by several critical factors, including the rising prevalence of drug-resistant bacterial infections, increasing hospital admissions, and advancements in antibiotic combination therapies. One of the primary growth drivers is the urgent need for effective treatment options against Gram-negative bacteria, which have shown increasing resistance to conventional antibiotics. As healthcare providers struggle to manage severe infections, carbapenems remain an essential component of antimicrobial therapy.

Another crucial driver shaping the market is the expansion of government and private sector funding for antibiotic research and development. Global health organizations and pharmaceutical companies are investing in innovative carbapenem formulations and resistance-fighting drug combinations to address the AMR crisis. Additionally, regulatory approvals for next-generation carbapenem-BLI combinations are expected to accelerate market growth, providing healthcare professionals with more targeted and effective treatment options. As the fight against AMR continues, the carbapenem market is poised for sustained expansion, driven by innovation, increasing demand for hospital-based treatments, and global efforts to preserve the effectiveness of last-resort antibiotics.

SCOPE OF STUDY:

The report analyzes the Carbapenem market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels); Application (Urinary Tract Infections Application, Bloodstream Infections Application, Intra-abdominal Infections Application, Pneumonia Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• ALPS Pharmaceutical Ind. Co., Ltd.
• AstraZeneca plc
• Asymchem Laboratories Inc.
• Aurobindo Pharma Ltd.
• Beijing Lunarsun Pharmaceutical Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Fresenius Kabi LLC
• GlaxoSmithKline plc
• High Science Co., Ltd.
• Jeil Pharmaceutical Co., Ltd.
• Meiji Holdings Co., Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Pharma Impex Laboratories Pvt. Ltd.
• Sandoz International GmbH
• Shionogi & Co., Ltd.
• Spero Therapeutics
• Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Carbapenem - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Multidrug-Resistant Infections Throws the Spotlight on Carbapenems as a Last-Resort Therapy
  • Escalating Global Antimicrobial Resistance (AMR) Crisis Propels Demand for Broad-Spectrum Carbapenem Antibiotics
  • Increasing Hospital-Acquired and ICU Infections Expands the Addressable Market for Carbapenem-Based Treatments
  • Surge in Gram-Negative Bacterial Infections Strengthens the Business Case for Carbapenem Usage in Critical Care
  • Growing Demand for Combination Therapies Drives Innovation in Carbapenem-Beta-Lactamase Inhibitor Products
  • Regulatory Push for Novel Antibiotic Development Fuels R&D in Next-Generation Carbapenem Analogs
  • Expansion of Hospital Formulary Listings and Stewardship Programs Enhances Clinical Access to Carbapenems
  • Increased Adoption in Emerging Markets Accelerates Global Market Penetration for Generic Carbapenem Brands
  • Pharmaceutical Industry Focus on Injectable Anti-Infectives Spurs Demand for Carbapenem Formulations
  • Rising Surgical Procedures and Immunocompromised Patient Populations Drive Empirical Use of Carbapenems
  • Patent Expiries and Generic Competition Drive Down Prices While Expanding Volume-Based Opportunities
  • Growing Carbapenem-Resistant Enterobacteriaceae (CRE) Incidence Creates Urgency for Stewarded Use and Alternatives
  • Rapid Diagnostic Advancements Enhance Targeted Use and Optimize Carbapenem Prescribing Practices
  • Increased Focus on Carbapenem Stewardship and Surveillance Systems Presents Both Regulatory and Market Challenges
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Carbapenem Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Carbapenem by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Meropenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Meropenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Meropenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Imipenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Imipenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Imipenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Ertapenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Ertapenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Ertapenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Intra-abdominal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Intra-abdominal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Intra-abdominal Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pneumonia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pneumonia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pneumonia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Urinary Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Bloodstream Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Bloodstream Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Bloodstream Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Carbapenem by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Carbapenem by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Carbapenem by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Carbapenem by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION